Dr. Tolulope Adewole is a consummate healthcare expert with over two decades of cognate experience spanning different aspects of the medical profession from the consulting room to c-suite roles.
He is an alumnus of the prestigious University of Ibadan where he undertook his undergraduate studies. He completed his medical internship at the Lagos University Teaching Hospital, Idi-Araba, before proceeding back to the University College Hospital, Ibadan for his Residency Program in Chemical Pathology where he obtained a Fellowship of the National Post-Graduate Medical College. He completed a certificate programme in Healthcare Management from the University of Washington and is a professional member of the American Association of Clinical Chemists amongst several other professional bodies. He is currently the Chairman of the Finance Committee of the Healthcare Federation of Nigeria.
In 2013, Dr. Adewole joined PathCare Nigeria (now SYNLAB) as a full-time Consultant Chemical Pathologist and rose to become its first Executive Director (Operations) in 2016 where he was responsible for driving business expansion as well as international re-accreditations of PathCare’s laboratories. Under his leadership, PathCare won many awards including the prestigious NHEA Laboratory awards from inception and back-to-back thereafter. Following the International merger-by-acquisition with Europe largest laboratory network, SYNLAB in 2018, Dr Adewole was elevated to the role of Chief Medical Officer and worked in this capacity until his resignation in October 2019.
He joined the NSIA Healthcare Development & Investment Company (NHDIC) as its pioneer Chief Executive Officer in 2019, where he has worked with an excellent and passionate team of highly skilled professionals under the guidance of the Board and Executive Management team of the NSIA. In this role, he led the operationalization of three landmark healthcare projects with a combined project development, construction, and equipping cost of US$21M.
The NHDIC healthcare projects currently cover Cancer care and Diagnostics and span across the three main regions in the country, specifically, the North, East and West of Nigeria. All three centre are co-located within and operated in collaboration with some of Nigeria’s leading teaching hospitals. The two diagnostic centres namely, the NSIA-Kano Diagnostic Centre and NSIA-Umuahia Diagnostic Centre are co-located with the Aminu Kano Teaching Hospital, Kano, and Federal Medical Centre, Umuahia, respectively. The cancer centre, NSIA-LUTH Cancer Centre is co-located within the grounds of the Lagos University Teaching Hospital, Idi-Araba.
Dr. Adewole is a professional with a proven track record in healthcare and is a respected resource person on healthcare issues both within and outside the country, He is highly regarded and has been recognized by various bodies including but not limited to the Institute of Directors, Society for Quality in Health Care, International Society for Immunotherapy of Cancer (SITC). Dr Adewole has been a participant of many international conferences on healthcare financing through PPPs and has been involved in collaborations across many healthcare financing agencies and international research groups.
He is an alumnus of the prestigious University of Ibadan where he undertook his undergraduate studies. He completed his medical internship at the Lagos University Teaching Hospital, Idi-Araba, before proceeding back to the University College Hospital, Ibadan for his Residency Program in Chemical Pathology where he obtained a Fellowship of the National Post-Graduate Medical College. He completed a certificate programme in Healthcare Management from the University of Washington and is a professional member of the American Association of Clinical Chemists amongst several other professional bodies. He is currently the Chairman of the Finance Committee of the Healthcare Federation of Nigeria.
In 2013, Dr. Adewole joined PathCare Nigeria (now SYNLAB) as a full-time Consultant Chemical Pathologist and rose to become its first Executive Director (Operations) in 2016 where he was responsible for driving business expansion as well as international re-accreditations of PathCare’s laboratories. Under his leadership, PathCare won many awards including the prestigious NHEA Laboratory awards from inception and back-to-back thereafter. Following the International merger-by-acquisition with Europe largest laboratory network, SYNLAB in 2018, Dr Adewole was elevated to the role of Chief Medical Officer and worked in this capacity until his resignation in October 2019.
He joined the NSIA Healthcare Development & Investment Company (NHDIC) as its pioneer Chief Executive Officer in 2019, where he has worked with an excellent and passionate team of highly skilled professionals under the guidance of the Board and Executive Management team of the NSIA. In this role, he led the operationalization of three landmark healthcare projects with a combined project development, construction, and equipping cost of US$21M.
The NHDIC healthcare projects currently cover Cancer care and Diagnostics and span across the three main regions in the country, specifically, the North, East and West of Nigeria. All three centre are co-located within and operated in collaboration with some of Nigeria’s leading teaching hospitals. The two diagnostic centres namely, the NSIA-Kano Diagnostic Centre and NSIA-Umuahia Diagnostic Centre are co-located with the Aminu Kano Teaching Hospital, Kano, and Federal Medical Centre, Umuahia, respectively. The cancer centre, NSIA-LUTH Cancer Centre is co-located within the grounds of the Lagos University Teaching Hospital, Idi-Araba.
Dr. Adewole is a professional with a proven track record in healthcare and is a respected resource person on healthcare issues both within and outside the country, He is highly regarded and has been recognized by various bodies including but not limited to the Institute of Directors, Society for Quality in Health Care, International Society for Immunotherapy of Cancer (SITC). Dr Adewole has been a participant of many international conferences on healthcare financing through PPPs and has been involved in collaborations across many healthcare financing agencies and international research groups.
Speaking In
9:00 AM - 10:00 AM
Thursday, June 8
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
